Iovance Biotherapeutics
IOVA
$4.07
-13.22%
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) therapies for solid tumor cancers, with its lead product, Amtagvi, approved for advanced melanoma. As a first-mover in autologous TIL cell therapy, Iovance holds a distinct competitive position in the immuno-oncology space, aiming to address high unmet medical needs. The current investor narrative centers on the commercial ramp of Amtagvi, pipeline expansion into other indications, and the company's path to profitability, with recent news highlighting both the potential for significant upside and the execution risks inherent in scaling a novel cell therapy. The stock has experienced substantial volatility, reflecting the high-risk, high-reward nature of the opportunity.…
IOVA
Iovance Biotherapeutics
$4.07
Related headlines
Investment Opinion: Should I buy IOVA Today?
Rating: Buy. Iovance is a high-risk, high-reward opportunity with a consensus Buy rating and an average target price of $8.80, implying 116% upside. The thesis is that Amtagvi's commercial ramp, combined with pipeline expansion, will drive revenue growth and eventually profitability, justifying the current valuation.
Sign up to view all
IOVA 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by strong revenue growth, attractive valuation on forward sales, and high gross margins. However, the company's unprofitability and negative cash flow temper confidence. If revenue growth continues at 40%+ and the company achieves profitability within 12-18 months, the stock could re-rate significantly. Conversely, any sign of commercial stagnation or pipeline failure would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Iovance Biotherapeutics's 12-month outlook, with a consensus price target around $8.22 and implied upside of +102.0% versus the current price.
Average Target
$8.22
0 analysts
Implied Upside
+102.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$4 - $14
Analyst target range
Iovance is covered by 10 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.6 (where 1 is Strong Buy and 5 is Sell). The average target price is $8.80, implying a 116% upside from the current price of $4.07. The target range is wide, from a low of $4.00 to a high of $14.00, indicating significant uncertainty. The high target of $14.00 assumes successful pipeline expansion and strong commercial uptake, while the low target of $4.00 reflects concerns about execution and competition. Recent ratings actions show a mix of Buy and Neutral ratings, with Chardan Capital maintaining a Buy and UBS holding Neutral, suggesting a generally positive but cautious sentiment. The wide target spread highlights the speculative nature of the stock, and the implied upside is substantial but carries high risk.
Bulls vs Bears: IOVA Investment Factors
Iovance presents a classic high-risk, high-reward biotech opportunity. The bull case is anchored by its first-mover status in TIL therapy, rapid revenue growth, and a strong balance sheet, while the bear case highlights persistent losses, negative cash flow, and execution risks. Currently, the bull case has stronger evidence given the accelerating revenue trend and analyst consensus, but the single most important tension is whether the company can scale Amtagvi's commercial adoption to achieve profitability before cash reserves deplete. If revenue growth continues at 40%+ and the company reaches breakeven, the stock could re-rate significantly; conversely, any stumble in commercial rollout or pipeline setbacks could trigger a sharp sell-off.
Bullish
- First-mover in TIL therapy with approved product: Iovance's Amtagvi is the first approved autologous TIL therapy for solid tumors, creating a unique competitive moat. The company's Q1 2026 revenue of $71.43 million, up 44.8% YoY, demonstrates early commercial traction, with product revenue of $0.5 million indicating initial patient uptake.
- Strong revenue growth trajectory: Revenue has grown from $31.11 million in Q2 2024 to $86.77 million in Q4 2025, a 179% increase over six quarters. The 44.8% YoY growth in Q1 2026, despite a seasonal dip, underscores the scalability of the therapy and expanding market adoption.
- High gross margin of 98.6%: The personalized nature of TIL therapy yields exceptional gross margins, with Q1 2026 gross margin at 98.6%. This indicates a highly profitable product once fixed costs are covered, providing a clear path to operating leverage as revenue scales.
- Analyst consensus Buy with 116% upside: With 10 analysts covering, the consensus is Buy (mean score 1.6) and the average target price is $8.80, implying 116% upside from the current $4.07. The high target of $14.00 suggests potential for even greater gains if pipeline milestones are met.
Bearish
- Persistent unprofitability and negative cash flow: Iovance reported a net loss of $79.05 million in Q1 2026, and TTM free cash flow is -$305.02 million. The company relies on equity financing, having raised $98.51 million in Q1 2026, which dilutes shareholders and raises concerns about long-term capital needs.
- High valuation on forward sales: Despite a trailing PS of 3.70, the forward PS of 0.79 implies the market expects revenue to reach $1.23 billion, a massive leap from current levels. If revenue growth disappoints, the stock could face significant de-rating.
- Execution risks in scaling novel therapy: The complex, personalized manufacturing process for TIL therapy poses operational challenges. Q1 2026 revenue declined sequentially from Q4 2025, and product revenue of only $0.5 million suggests early adoption is slower than hoped, raising concerns about commercial execution.
- Wide analyst target range indicates uncertainty: Analyst targets range from $4.00 to $14.00, a 250% spread, reflecting high uncertainty about the company's future. The low target is essentially at the current price, suggesting some analysts see limited upside, while the high target assumes flawless execution.
IOVA Technical Analysis
Iovance's stock is in a strong uptrend over the past year, with a 1-year price change of +58.37%, significantly outperforming the S&P 500's +18.19% gain. The current price of $4.07 sits at 61.3% of its 52-week range (between $1.76 low and $5.64 high), indicating the stock is in the upper half of its range but not at extremes. This positioning suggests sustained bullish momentum, though the stock has pulled back from its recent high, which may present a buying opportunity or signal near-term consolidation.
Beta
0.69
0.69x market volatility
Max Drawdown
-54.4%
Largest decline past year
52-Week Range
$2-$6
Price range past year
Annual Return
+58.4%
Cumulative gain past year
| Period | IOVA Return | S&P 500 |
|---|---|---|
| 1m | +2.5% | +0.3% |
| 3m | +19.7% | +4.0% |
| 6m | +59.6% | +8.3% |
| 1y | +58.4% | +20.2% |
| ytd | +61.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IOVA Fundamental Analysis
Iovance's revenue is growing rapidly, with Q1 2026 revenue of $71.43 million, up 44.8% year-over-year from $49.32 million in Q1 2025. The multi-quarter trend shows accelerating growth: revenue increased from $31.11 million in Q2 2024 to $86.77 million in Q4 2025, though Q1 2026 saw a sequential decline from Q4 2025. This growth is driven by the commercial launch of Amtagvi, with product revenue of $0.5 million in the latest quarter, indicating early but promising uptake. The company remains unprofitable, with a net loss of $79.05 million in Q1 2026, though the net loss has narrowed from $116.16 million in Q1 2025. Gross margin is exceptionally high at 98.6%, reflecting the personalized nature of TIL therapy, but operating margin is deeply negative at -153.1% due to heavy R&D and SG&A expenses. The balance sheet shows a current ratio of 3.20, indicating strong liquidity, and a low debt-to-equity ratio of 0.069, suggesting minimal leverage. However, free cash flow is negative at -$305.02 million TTM, and the company relies on equity financing, having raised $98.51 million in Q1 2026, which dilutes shareholders but supports ongoing operations.
Quarterly Revenue
$71430000.0B
2026-03
Revenue YoY Growth
+44.8%
YoY Comparison
Gross Margin
98.6%
Latest Quarter
Free Cash Flow
$-305021000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IOVA Overvalued?
Given Iovance's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 3.70, while the forward PS ratio (based on estimated revenue of $1.23 billion) is approximately 0.79, implying the market expects significant revenue growth. The EV/Sales ratio is 6.40, reflecting a premium to the PS ratio due to the company's cash position. Compared to the biotechnology industry average PS ratio of around 5.0 (based on typical data), Iovance's trailing PS of 3.70 is at a 26% discount, but the forward PS of 0.79 suggests the market is pricing in substantial future revenue. Historically, Iovance's PS ratio has ranged from 0 to 73.8 over the past five years, with the current trailing PS of 3.70 near the lower end of that range, indicating the stock is relatively cheap on a historical basis. This suggests the market may be undervaluing the company's growth potential, or it reflects the high risk associated with commercial execution.
PE
-2.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial: Iovance is unprofitable with a net loss of $79.05 million in Q1 2026, and TTM free cash flow is -$305.02 million. The company's operating margin is deeply negative at -153.1%, and it relies on equity financing, having raised $98.51 million in Q1 2026, which dilutes shareholders. While the current ratio of 3.20 provides near-term liquidity, the ongoing cash burn rate of approximately $300 million per year implies the need for additional capital raises, potentially at unfavorable terms. Revenue concentration is also a risk, as Amtagvi is the sole commercial product, and its early uptake (product revenue of $0.5 million) is minimal, leaving the company vulnerable to any commercial setbacks.